TSX runs higher on rate cut expectations
Autonomix Medical, Inc. (NASDAQ:AMIX) announced Monday that it has increased the aggregate sales price of shares that may be sold under its At Market Issuances Sales Agreement with Ladenburg Thalmann & Co. Inc. by $1.4 million. The agreement, initially entered into on July 26, 2024, previously allowed the company to sell shares of its common stock with an aggregate sales price of up to $2.1 million. With the adjustment, the total aggregate sales price now stands at $3.5 million.
According to the company’s statement, any sales of shares under the agreement will be made pursuant to Autonomix Medical’s effective shelf registration statement on Form S-3 (File No. 333-285464), which became effective on March 11, 2025. The registration statement includes a base prospectus and a related prospectus supplement that was filed with the Securities and Exchange Commission on Monday.
Autonomix Medical is incorporated in Delaware and is based in The Woodlands, Texas. The company’s common stock trades on the Nasdaq Stock Market under the symbol AMIX.
This information is based on a press release statement included in the company’s recent SEC filing.
In other recent news, Autonomix Medical, Inc. has made significant strides in its technological advancements and financial activities. The company announced it has completed the final design review of its nerve-sensing catheter, preparing it for human clinical trials. This intravascular device aims to improve nerve treatment precision by detecting nerve signals in real time. Autonomix also raised approximately $2.5 million through a warrant exercise deal, involving the purchase of over 1.4 million shares at a reduced price. Furthermore, the company has been granted a U.S. patent for its "Smart Torquer" technology, enhancing the manipulation of intravascular devices during procedures. In addition, Autonomix received another U.S. patent for its nerve-sensing medical technology, which includes systems for neurological evaluation and modification. These developments reflect the company’s ongoing efforts to innovate in the field of medical devices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.